About FreeOx Biotech

The startup develops cerebrovascular protective therapies that utilize a neuroprotective molecule to mitigate oxidative stress in the neurological and cardiovascular systems. This therapy effectively prevents damage caused by reperfusion after a stroke, enabling patients to recover without disabilities.

```xml <problem> Despite advancements in acute ischemic stroke (AIS) treatment, including mechanical thrombectomy (MT), a significant proportion of patients still experience long-term disability due to inadequate brain microcirculation and reperfusion following the procedure. Current therapies often fail to fully restore functional independence, leading to increased healthcare costs and reduced quality of life for stroke survivors. </problem> <solution> FreeOx Biotech is developing cerebrovascular protective therapeutics, with its lead asset, Ox-01, a carefully engineered formulation of Uric Acid (UA), designed as an emergency adjunct therapy to Mechanical Thrombectomy (MT) for the treatment of Acute Ischemic Stroke (AIS). Ox-01 is administered via a 90-minute IV infusion before or during MT to enhance brain microcirculation and boost penumbra reperfusion through a multi-modal mechanism of action. By improving microcirculation, Ox-01 aims to increase the number of patients achieving functional independence post-stroke, addressing a critical unmet need in stroke care. FreeOx Biotech also has Lip-Ox, a proprietary liposomal formulation technology based on Uric Acid, which has the unique ability to induce superior drug characteristics (e.g., cross the blood-brain barrier), making it a versatile multi-product/multi indication platform for our future. </solution> <features> - Ox-01: Pharmaceutical-grade Uric Acid formulation designed for IV infusion during mechanical thrombectomy - Enhances brain microcirculation and boosts penumbra reperfusion - Demonstrated a 19% increase in patients achieving good outcomes (independent living) in a Phase IIb clinical trial - Lip-Ox: Proprietary liposomal formulation technology based on Uric Acid - Lip-Ox is designed to customize a sustained release mechanism and a shift to simple IV injection, both ideal for non-emergency indications in neurology. - Granted use patent covering Uric Acid with MT in the US, South Korea and Australia - Intellectual protection covers proprietary API synthesis GMP process and pharmaceutical product formulation process </features> <target_audience> The primary target audience includes stroke neurologists, interventional neuroradiologists, and hospitals specializing in acute stroke care, seeking to improve patient outcomes following mechanical thrombectomy for acute ischemic stroke. </target_audience> ```

What does FreeOx Biotech do?

Where is FreeOx Biotech located?

FreeOx Biotech is based in Barcelona, Spain.

When was FreeOx Biotech founded?

FreeOx Biotech was founded in 2017.

How much funding has FreeOx Biotech raised?

FreeOx Biotech has raised 2420000.

Location

Barcelona, Spain

Founded

2017

Funding

2420000

Employees

5 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

FreeOx Biotech

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

freeoxbiotech.com 300+

Crunchbase

Founded 2017 – Barcelona, Spain

Funding

Estimated Funding

$2M+

Team (5+)

No team information available.

Company Description

Problem

Despite advancements in acute ischemic stroke (AIS) treatment, including mechanical thrombectomy (MT), a significant proportion of patients still experience long-term disability due to inadequate brain microcirculation and reperfusion following the procedure. Current therapies often fail to fully restore functional independence, leading to increased healthcare costs and reduced quality of life for stroke survivors.

Solution

FreeOx Biotech is developing cerebrovascular protective therapeutics, with its lead asset, Ox-01, a carefully engineered formulation of Uric Acid (UA), designed as an emergency adjunct therapy to Mechanical Thrombectomy (MT) for the treatment of Acute Ischemic Stroke (AIS). Ox-01 is administered via a 90-minute IV infusion before or during MT to enhance brain microcirculation and boost penumbra reperfusion through a multi-modal mechanism of action. By improving microcirculation, Ox-01 aims to increase the number of patients achieving functional independence post-stroke, addressing a critical unmet need in stroke care. FreeOx Biotech also has Lip-Ox, a proprietary liposomal formulation technology based on Uric Acid, which has the unique ability to induce superior drug characteristics (e.g., cross the blood-brain barrier), making it a versatile multi-product/multi indication platform for our future.

Features

Ox-01: Pharmaceutical-grade Uric Acid formulation designed for IV infusion during mechanical thrombectomy

Enhances brain microcirculation and boosts penumbra reperfusion

Demonstrated a 19% increase in patients achieving good outcomes (independent living) in a Phase IIb clinical trial

Lip-Ox: Proprietary liposomal formulation technology based on Uric Acid

Lip-Ox is designed to customize a sustained release mechanism and a shift to simple IV injection, both ideal for non-emergency indications in neurology.

Granted use patent covering Uric Acid with MT in the US, South Korea and Australia

Intellectual protection covers proprietary API synthesis GMP process and pharmaceutical product formulation process

Target Audience

The primary target audience includes stroke neurologists, interventional neuroradiologists, and hospitals specializing in acute stroke care, seeking to improve patient outcomes following mechanical thrombectomy for acute ischemic stroke.